<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30799">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02705755</url>
  </required_header>
  <id_info>
    <org_study_id>0145</org_study_id>
    <nct_id>NCT02705755</nct_id>
  </id_info>
  <brief_title>TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)</brief_title>
  <official_title>A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma R &amp; D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma R &amp; D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multiple-center, randomized, 2-part, single- and double-blind study will be conducted
      in male and female subjects with neurogenic orthostatic hypotension to evaluate the effect
      of TD-9855 in improving symptoms of orthostatic intolerance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seated systolic blood pressure</measure>
    <time_frame>6 to 8 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>57 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neurogenic Orthostatic Hypotension</condition>
  <arm_group>
    <arm_group_label>TD-9855 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple doses of TD-9855 and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-9855 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple doses of TD-9855 and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-9855</intervention_name>
    <arm_group_label>TD-9855 Cohort 1</arm_group_label>
    <arm_group_label>TD-9855 Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>TD-9855 Cohort 1</arm_group_label>
    <arm_group_label>TD-9855 Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with symptomatic orthostatic hypotension due to Parkinson's disease,
             multiple system atrophy, or pure autonomic failure, (i.e. neurogenic orthostatic
             hypotension)

          -  At screening, subject must meet the diagnostic criteria of neurogenic orthostatic
             hypotension, as demonstrated by a â‰¥ 30 mm Hg drop in systolic blood pressure (SBP)
             within 5 minutes of standing

          -  Impaired autonomic reflexes, as determined by absence of BP overshoot during phase IV
             of the Valsalva maneuver

        Exclusion Criteria:

          -  Systemic illnesses known to produce autonomic neuropathy, including but not limited
             to diabetes mellitus, amyloidosis, monoclonal gammopathy of unknown significance, and
             autoimmune neuropathies.

          -  Concomitant use of vasoconstricting agents for the purpose of increasing BP such as
             ephedrine, dihydroergotamine, or midodrine must stop taking these drugs at least 2
             days or five half-lives (whichever is longer) prior to dosing on Day 1 and throughout
             the duration of the study.

          -  Concomitant use of anti-hypertensive medication for the treatment of essential
             hypertension unrelated to autonomic dysfunction.

          -  Known or suspected alcohol or substance abuse within the past 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ross Vickery, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma Antibiotics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wayne Yates</last_name>
    <phone>650-808-6000</phone>
    <email>wyates@theravance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Martinez</last_name>
      <phone>212-263-7225</phone>
      <email>Jose.Martinez@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Horacio Kaufmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonnie K. Black, RN, ANP</last_name>
      <phone>615-343-6862</phone>
      <email>Bonnie.Black@Vanderbilt.Edu</email>
    </contact>
    <investigator>
      <last_name>Italo Biaggioni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 11, 2016</lastchanged_date>
  <firstreceived_date>March 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
